Management of HBV infection in liver transplantation patients

International Journal of Medical Sciences

Volumn 2, Issue 1, 2005, Pages 41-49

  Vierling, John M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Immusol Inc   (United States)

Author keywords

HBV Infection; Liver Transplantation; Patient Management

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; CYCLOSPORIN; ENTECAVIR; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE; NUCLEOTIDE; RNA DIRECTED DNA POLYMERASE; STEROID; TACROLIMUS; TENOFOVIR DISOPROXIL;

ACTIVE IMMUNIZATION; ALLOGRAFT; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; GRAFT INFECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RESISTANCE; INFECTION RISK; ISCHEMIA; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM CARE; MONOTHERAPY; MULTIVARIATE ANALYSIS; NEUTROPENIA; ORGAN DONOR; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; RECIPIENT; RECURRENT DISEASE; REINFECTION; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURGICAL PATIENT; SURVIVAL; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME; TREATMENT PLANNING; VACCINATION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 21744438439     PISSN: 14491907     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.2.41     Document Type: Review

References (115)

1. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13(4):619-626.
2. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14(1):104-111.
3. Belle SH, Beringer KC, Murphy JB, Detre KM. The Pitt-UNOS Liver Transplant Registry. Clin Transpl 1992;17-32.
4. Van Thiel DH, Schade RR, Gavaler JS, Shaw BW Jr., Iwatsuki S, Starzl TE. Medical aspects of liver transplantation. Hepatology 1984;4(1 Suppl):79S-83S.
5. [No authors listed]. Medicare program; criteria for Medicare coverage of adult liver transplants - HCFA. Final notice. Fed Regist 1991; 56(71):15006-15018.
6. Villamil FG. Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. J Hepatol 2003; 39(4):466-474.
7. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004; 24 (Suppl 1):55-62.
8. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10(8):968.
9. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329(25):1842-1847.
10. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24(6):1327-1333.
11. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61(9):1358-1364.
12. Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227(6):841-850.
13. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35(6):1528-1535.
14. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6(6):741-748.
15. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34(6):903-910.
16. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29(5):1581-1586.
17. Terrault NA. Treatment of recurrent hepatitis B infection in liver transplant recipients. Liver Transpl 2002; 8(10 Suppl 1):S74-S81.
18. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6(4):429-433.
19. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32(1):129-134.
20. Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7(1):51-58.
21. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113(5):1668-1674.
22. Cavallari A, De Raffele E, Bellusci R, Miniero R, Vivarelli M, Galli S et al. De novo hepatitis B and C viral infection after liver transplantation. World J Surg 1997; 21(1):78-84.
23. Crespo J, Fabrega E, Casafont F, Rivero M, Heras G, de la PJ et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999; 5(3):175-183.
24. Fabia R, Levy MF, Crippin J, Tillery W, Netto GJ, Aguanno J et al. De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. Liver Transpl Surg 1998; 4(2):119-127.
25. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002; 235(5):611-619.
26. Jacobs JM, Martin P, Munoz SJ, Westerberg S, Hann HW, Moritz MJ et al. Liver transplantation for chronic hepatitis B in Asian males. Transplant Proc 1993; 25(2):1904-1906.
27. Teo EK, Han SH, Terrault N, Luketic V, Jensen D, Keeffe EB et al. Liver transplantation in patients with hepatitis B virus infection: outcome in Asian versus white patients. Hepatology 2001; 34(1):126-132.
28. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38(1):86-95.
29. Feray C, Zignego AL, Samuel D, Bismuth A, Reynes M, Tiollais P et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990; 49(6):1155-1158.
30. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32(6):1189-1195.
31. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27(1):213-222.
32. Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998; 28(2):555-561.
33. Seehofer D, Rayes N, Steinmuller T, Muller AR, Settmacher U, Neuhaus R et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001; 7(11):976-982.
34. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122(2):264-273.
35. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39(6):1085-1089.
36. Girlanda R, Mohsen AH, Smith H, Sablon E, Yuen MF, O'Grady J et al. Hepatitis B virus genotype A and D and clinical outcomes of liver transplantation for HBV-related disease. Liver Transpl 2004; 10(1):58-64.
37. Ben Ari Z, Ashur Y, Daudi N, Shmilovitz-Wiess H, Brown M, Sulkes J et al. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation. Clin Transplant 2004; 18(4):415-422.
38. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104(4):1116-1121.
39. Tchervenkov JI, Tector AJ, Barkun JS, Sherker A, Forbes CD, Elias N et al. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 1997; 226(3):356-365.
40. Hassanein T, Colantoni A, De Maria N, Van Thiel DH. Interferon-alpha 2b improves short-term survival in patients transplanted for chronic liver failure caused by hepatitis B. J Viral Hepat 1996; 3(6):333-340.
41. Berenguer M, Prieto M, Rayon M, Bustamante M, Carrasco D, Moya A et al. Famciclovir treatment in transplant recipients with HBV-related liver disease: disappointing results. Am J Gastroenterol 2001; 96(2):526-533.
42. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348(9036):1212-1215.
43. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28(2):585-589.
44. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31(1):207-210.
45. Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233(2):276-281.
46. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33(2):424-432.
47. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34(2):411-416.
48. Seehofer D, Rayes N, Naumann U, Neuhaus R, Muller AR, Tullius SG et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001; 72(8):1381-1385.
49. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34(6):895-902.
50. Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley KV et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8(5):433-439.
51. Andreone P, Biselli M, Gramenzi A, Cursaro C, Morelli MC, Sama C et al. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation 2002; 74(8):1119-1124.
52. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123(3):719-727.
53. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333(25):1657-1661.
54. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24(3):714-717.
55. Starkel P, Horsmans Y, Geubel A, Ciccarelli O, Goubau P, Rahier J et al. Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to the emergence of a hepatitis B YMDD escape mutant virus. J Hepatol 2001; 35(5):679-681.
56. Saab S, Kim M, Wright TL, Han SH, Martin P, Busuttil RW. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000; 119(5):1382-1384.
57. Barcena MR, Cid GL, Lopez SP. Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine. Transplant Proc 2003; 35(5):1841-1843.
58. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2(3):266-272.
59. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33(2):301-307.
60. Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33(2):308-312.
61. Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003; 63(20):2215-2234.
62. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38(6):1419-1427.
63. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125(2):292-297.
64. Thompson CA. Prodrug of tenofovir diphosphate approved for combination HIV therapy. Am J Health Syst Pharm 2002; 59(1):18.
65. Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189(7):1185-1192.
66. Van Bommel F, Schernick A, Hopf U, Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 2003; 124(2):586-587.
67. Van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36(2):507-508.
68. Bruno R, Sacchi P, Zocchetti C, Ciappina V, Puoti M, Filice G. Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'eminus' patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS 2003; 17(5):783-784.
69. Honkoop P, de Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs 2003; 12(4):683-688.
70. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123(6):1831-1838.
71. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48(9):3498-3507.
72. Pruett T. Indefinite passive immunization after liver transplantation for hepatitis B. Liver Transpl 2002; 8(10 Suppl 1):S88-S89.
73. Terrault NA, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 2003; 7(3):537-550.
74. Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9(2):182-187.
75. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5(6):491-496.
76. Lowell JA, Burgess S, Shenoy S, Curci JA, Peters M, Howard TK. Mercury poisoning associated with high-dose hepatitis-B immune globulin administration after liver transplantation for chronic hepatitis B. Liver Transpl Surg 1996; 2(6):475-478.
77. Kalinina T, Iwanski A, Will H, Sterneck M. Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. Hepatology 2003; 38(5):1274-1281.
78. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000; 70(5):809-815.
79. Malkan G, Cattral MS, Humar A, Al Asghar H, Greig PD, Hemming AW et al. Lamivudine for hepatitis B in liver transplantation: a singlecenter experience. Transplantation 2000; 69(7):1403-1407.
80. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5(6):520-525.
81. McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5(6):512-519.
82. Roche B, Samuel D. Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results. J Hepatol 2003; 39 (Suppl 1):S181-S189.
83. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004; 77(8):1203-1208.
84. Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff ER et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7(6):504-510.
85. Jurim O, Martin P, Winston DJ, Shackleton C, Holt C, Feller J et al. Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection. Liver Transpl Surg 1996; 2(5):370-374.
86. Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34(6):888-894.
87. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38(6):811-817.
88. Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6(4):434-439.
89. Ilan Y, Nagler A, Adler R, Naparstek E, Or R, Slavin S et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 1993; 18(2):246-252.
90. Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 1993; 104(6):1818-1821.
91. Dahmen U, Dirsch O, Li J, Fiedle M, Lu M, Rispeter K et al. Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation 2004; 77(7):965-972.
92. Toniutto P, Fumo E, Caldato M, Apollonio L, Perin A, Pirisi M. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 2004; 77(3):472-473.
93. Sanchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31(2):496-501.
94. Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35(1):176-181.
95. Chang SH, Suh KS, Yi NJ, Choi SH, Lee HJ, Seo JK et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003; 37(6):1329-1334.
96. Bienzle U, Gunther M, Neuhaus R, Vandepapeliere P, Vollmar J, Lun A et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003; 38(4):811-819.
97. Tur-Kaspa R, Shaul Y, Moore DD, Burk RD, Okret S, Poellinger L et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988; 167(2):630-633.
98. Everson GT, Trouillot T, Wachs M, Bak T, Steinberg T, Kam I et al. Early steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl Surg 1999; 5(4 Suppl 1):S48-S57.
99. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002; 8(10 Suppl 1):S82-S87.
100. Saab S, Chang AJ, Comulada S, Geevarghese SK, Anselmo RD, Durazo F et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003; 9(10):1053-1061.
101. Fabrega E, Garcia-Suarez C, Guerra A, Orive A, Casafont F, Crespo J et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 2003; 9(9):916-920.
102. Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7(6):513-517.
103. Lo CM, Fan ST, Liu CL, Yong BH, Wong Y, Ng IO et al. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl 2003; 9(8):827-832.
104. Hwang S, Moon DB, Lee SG, Park KM, Kim KH, Ahn CS et al. Safety of anti-hepatitis B core antibody-positive donors for living-donor liver transplantation. Transplantation 2003; 75(3 Suppl):S45-S48.
105. Beckebaum S, Malago M, Dirsch O, Cicinnati VR, Trippler M, Lampertico P et al. Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. Clin Transplant 2003; 17(6):554-559.
106. de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001; 34(3):578-582.
107. Wolters LM, Hansen BE, Niesters HG, Dehertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002; 37(1):137-144.
108. Seehofer D, Rayes N, Berg T, Neuhaus R, Hopf U, Muller AR et al. Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report. Transplantation 2000; 69(8):1739-1742.
109. Ben Ari Z, Shmueli D, Shapira Z, Mor E, Tur-Kaspa R. Loss of serum HBsAg after interferon-A therapy in liver transplant patients with recurrent hepatitis-B infection. Liver Transpl Surg 1997; 3(4):394-397.
110. Terrault NA, Holland CC, Ferrell L, Hahn JA, Lake JR, Roberts JP et al. Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg 1996; 2(2):132-138.
111. Roche B, Samuel D, Gigou M, Feray C, Virot V, Majno P et al. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. J Hepatol 1999; 31(4):584-592.
112. Gish RG, Lau JY, Brooks L, Fang JW, Steady SL, Imperial JC et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996; 23(1):1-7.
113. Rayes N, Seehofer D, Bechstein WO, Muller AR, Berg T, Neuhaus R et al. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation. Clin Transplant 1999; 13(6):447-452.
114. Gow PJ, Mutimer DJ. De novo hepatitis B infection acquired during liver transplantation. QJM 2001; 94(5):271-275.
115. Castells L, Vargas V, Rodriguez F, Allende H, Buti M, Sanchez-Avila JF et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002; 8(10):892-900.